Tudor Investment Corporation »

Protagonist Therapeutics shares owned by Tudor Investment Corporation

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by Tudor Investment Corporation from 13F filings

Historical chart of Tudor Investment Corporation investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by Tudor Investment Corporation consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by Tudor Investment Corporation

Quarter filed Position value Share count Share price at filing
2023-12-31 $660k 29k 22.93
2023-06-30 $921k 33k 27.62
2023-03-31 $859k 37k 23.00
2022-09-30 $205k 24k 8.43

More positions owned by Tudor Investment Corporation

Ishares Russell 2000 Etf - US ETP ETF Option Call Option (IWM)
Splunk Inc - US Equity
Pioneer Natural Resources Co - US Equity (PXD)
Financial Select Sector Spdr Fund - US ETP ETF Option Call Option (XLF)
Ishares Msci Emerging Markets Etf - US ETP ETF Option Call Option (EEM)
Spdr Dow Jones Industrial Average Etf Trust - US E ETF Option Call Option (DIA)
Exxon Mobil Corp - US Equity (XOM)
Meta Platforms Inc - US Equity (META)
Bristol-Myers Squibb Co - US Equity (BMY)
Texas Instruments Inc - US Equity Option Call Option (TXN)
Enphase Energy Inc - US Equity Option Call Option (ENPH)
United Parcel Service Inc - US Class B Equity Option Call Option (UPS)
Nvidia Corp - US Equity (NVDA)
Bank Of America Corp - US Equity (BAC)
Estee Lauder Cos Inc/The - US Equity (EL)

View all positions for Tudor Investment Corporation

Top funds holding Protagonist Therapeutics

BVF
Vanguard Group
Point72 Asset Management
Kynam Capital Management
Cowen And Company
Deutsche Bank Aktiengesellschaft
T. Rowe Price Associates
Dimensional Fund Advisors
683 Capital Management
Candriam Luxembourg S.C.A.
Goldman Sachs Group
Charles Schwab Investment Management
Citadel Advisors
Jpmorgan Chase & Co
Gratus Capital

View all funds holding Protagonist Therapeutics